<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020665</url>
  </required_header>
  <id_info>
    <org_study_id>KB-ENTO-3001</org_study_id>
    <secondary_id>2021-000761-33</secondary_id>
    <nct_id>NCT05020665</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kronos Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kronos Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO)&#xD;
      compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1&#xD;
      mutated (NPM1-m) acute myeloid leukemia (AML), as defined by the rate of molecularly defined&#xD;
      measurable residual disease (MRD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, international, double-blind, placebo-controlled study in&#xD;
      previously untreated participants with acute myeloid leukemia (AML) harboring nucleophosmin-1&#xD;
      (NPM1) mutations. Upon fulfillment of all eligibility criteria, participants will be&#xD;
      randomized 1:1 to receive intensive chemotherapy in combination with either the spleen&#xD;
      tyrosine kinase (SYK) inhibitor entospletinib (ENTO), or placebo. The study will consist of&#xD;
      Screening, Induction, Consolidation, End-of-Treatment, and Long-term Follow-up phases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurable Residual Disease (MRD) Negative Complete Response (CR) Rate</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 42 (cycle is 42 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival (RFS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Experience a Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Cycle 1 Day 1 to 30 days after last study treatment, cycle is 42 days (up to a maximum of 219 days)</time_frame>
    <description>Clinically significant changes in safety laboratory assessments, electrocardiograms (ECGs), echocardiogram (ECHO) / multi-gated acquisition (MUGA) scans and Eastern Cooperative Oncology Group performance status (ECOG PS) findings, as assessed by the Investigator, will be recorded as TEAEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Nucleophosmin 1-mutated Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Intensive Chemotherapy + Entospletinib (ENTO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with entospletinib (ENTO).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Chemotherapy + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with the matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>Orally as tablets</description>
    <arm_group_label>Intensive Chemotherapy + Entospletinib (ENTO)</arm_group_label>
    <other_name>ENTO</other_name>
    <other_name>GS-9973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally as tablets</description>
    <arm_group_label>Intensive Chemotherapy + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Continuous infusion</description>
    <arm_group_label>Intensive Chemotherapy + Entospletinib (ENTO)</arm_group_label>
    <arm_group_label>Intensive Chemotherapy + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthracycline</intervention_name>
    <description>Either daunorubicin or idarubicin will be administered via slow intravenous (IV) push</description>
    <arm_group_label>Intensive Chemotherapy + Entospletinib (ENTO)</arm_group_label>
    <arm_group_label>Intensive Chemotherapy + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 to 75 years with previously untreated de novo acute myeloid leukemia (AML),&#xD;
             AML with myelodysplastic syndromes (MDS) features, or therapy-related AML.&#xD;
&#xD;
          2. Nucleophosmin-1 (NPM1)-mutated disease documented in a local or the Sponsor's central&#xD;
             testing facility.&#xD;
&#xD;
             Note: Participants with concurrent FMS-like tyrosine kinase 3 (FLT3) mutation but&#xD;
             without access to midostaurin (eg, either for lack of health authority approval or&#xD;
             reimbursement) may also enroll; participants with a concurrent FLT3 mutation will not&#xD;
             be allowed to receive a FLT3 inhibitor at any time during the study treatment period.&#xD;
&#xD;
             Note: Participants with local test results for nucleophosmin-1 mutated (NPM1-m)&#xD;
             (and/or FLT3 mutational status) may enroll, provided appropriate samples are sent to&#xD;
             the Sponsor's central testing facility for NPM1-m companion diagnostic development.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0, 1, or 2.&#xD;
&#xD;
          4. Adequate hepatic and renal function defined as:&#xD;
&#xD;
               1. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 2.5&#xD;
                  times the upper limit of normal (ULN), except those with hepatic involvement by&#xD;
                  AML, as documented by either computed tomography (CT) or ultrasound, in whom&#xD;
                  levels of AST and ALT &lt; 5 times ULN are acceptable; total bilirubin &lt; 1.5 times&#xD;
                  ULN unless elevated due to Gilbert's Disease or hemolysis.&#xD;
&#xD;
               2. Calculated creatinine clearance &gt; 40 mL/min or serum creatinine &lt; 1.5 times ULN.&#xD;
&#xD;
          5. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and international&#xD;
             normalized ratio (INR) ≤ 1.5 x ULN unless receiving therapeutic anticoagulation.&#xD;
&#xD;
          6. Left ventricular ejection fraction ≥ 45% confirmed by echocardiogram (ECHO) or&#xD;
             multi-gated acquisition (MUGA) scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Isolated myeloid sarcoma (ie, participants must have peripheral blood and/or bone&#xD;
             marrow involvement by AML) or acute promyelocytic leukemia.&#xD;
&#xD;
          2. Known central nervous system (CNS) involvement with leukemia.&#xD;
&#xD;
          3. Active infection with hepatitis B, C, or known human immunodeficiency virus (HIV).&#xD;
&#xD;
          4. Known active coronavirus disease 2019 (COVID-19) either symptomatic or asymptomatic,&#xD;
             as determined by nasopharyngeal swab for severe acute respiratory syndrome (SARS)&#xD;
             coronavirus 2 (SARS CoV-2) ribonucleic acid (RNA) or antigen.&#xD;
&#xD;
             Note: Participants with a history of SARS-CoV-2 nasopharyngeal carriage (either with&#xD;
             or without symptoms), who have subsequently tested negative on follow-up&#xD;
             nasopharyngeal swab and are without signs or symptoms of COVID-19 may enroll.&#xD;
             Participants who are fully vaccinated against SARS-CoV-2 may enroll.&#xD;
&#xD;
          5. Disseminated intravascular coagulation with active bleeding or signs of thrombosis.&#xD;
&#xD;
          6. History of prior allogeneic hematopoietic stem cell transplant or solid organ&#xD;
             transplant.&#xD;
&#xD;
          7. Treatment with proton pump inhibitors (PPIs) from 7 days prior to enrollment until 48&#xD;
             hours after completion of entospletinib (ENTO) or placebo.&#xD;
&#xD;
             Note: PPIs are likely to interfere with ENTO absorption, thus requiring a 7-day&#xD;
             washout period. Histamine (H2) receptor antagonists and antacids are allowed for use&#xD;
             during the study treatment period.&#xD;
&#xD;
          8. Ongoing immunosuppressive therapy, including systemic chemotherapy for treatment of&#xD;
             leukemia.&#xD;
&#xD;
             Note: Participants may not receive AML-directed therapy prior to enrollment other than&#xD;
             hydroxyurea or leukapheresis for acute management of hyperleukocytosis.&#xD;
&#xD;
          9. Clinical signs/symptoms of leukostasis that have failed therapy including hydroxyurea&#xD;
             and/or leukapheresis of at least 3 days duration.&#xD;
&#xD;
         10. Clinically significant heart disease defined as:&#xD;
&#xD;
               1. New York Heart Association Class 3 or 4 congestive heart failure,&#xD;
&#xD;
               2. Acute myocardial infarction ≤ 6 months before enrollment,&#xD;
&#xD;
               3. Symptomatic cardiac ischemia/unstable angina ≤ 3 months before enrollment,&#xD;
&#xD;
               4. History of clinically significant arrhythmias (eg, ventricular tachycardia or&#xD;
                  fibrillation; Torsades de Pointe) including Mobitz type II 2nd degree or 3rd&#xD;
                  degree heart block without a permanent pacemaker in place.&#xD;
&#xD;
         11. Participants with a corrected congenital long measure between Q wave and T wave in the&#xD;
             electrocardiogram (QT) interval (using the Fredericia formula, Fridericia correction&#xD;
             of the QT measure [QTcF]) &gt; 480 msec or Long QT Syndrome.&#xD;
&#xD;
         12. Evidence of ongoing, uncontrolled systemic bacterial, fungal, or viral infection at&#xD;
             the time of study treatment initiation, including but not limited to persistent fever&#xD;
             or positive cultures in the setting of appropriate antimicrobial therapy.&#xD;
&#xD;
         13. Unable to swallow tablets or concurrent disease affecting gastrointestinal function&#xD;
             such as, malabsorption syndrome, gastric or small bowel resection, bariatric surgery,&#xD;
             inflammatory bowel disease, or bowel obstruction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director of Clinical Operations</last_name>
    <phone>650-484-1583</phone>
    <email>clinicaltrials@kronosbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Nucleophosmin 1-mutated Acute Myeloid Leukemia</keyword>
  <keyword>Entospletinib</keyword>
  <keyword>ENTO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

